Skip to main content
SpringerLink
Log in

Therapeutic Drug Monitoring of Phenytoin Rationale and Current Status

  • Leading Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Allen JP, Ludden TM, Burrow SR, Clementi WA, Stavchansky SA. Phenytoin cumulation kinetics. Clinical Pharmacology and Therapeutics 26: 445–448, 1979

    PubMed  CAS  Google Scholar 

  • Anavekar SN, Saunders RH, Wardell WM, Shoulson I, Emmings FG, et al. Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations. Clinical Pharmacology and Therapeutics 24: 629–637, 1978

    PubMed  CAS  Google Scholar 

  • Argyle JC, Kinniburgh DW, Costa R, Jennison T. Evaluation of an ultrafiltration-fluorescence polarization immunoassay for monitoring unbound phenytoin. Therapeutic Drug Monitoring 6: 117–120, 1984

    Article  PubMed  CAS  Google Scholar 

  • Baird-Lambert J, Manglick MP, Wall M, Buchanan N. Identifying patients who might benefit from free phenytoin monitoring. Therapeutic Drug Monitoring 9: 134–138, 1987

    Article  PubMed  CAS  Google Scholar 

  • Barth N, Alvan G, Borga O, Sjoqvist F. Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clinical Pharmacokinetics 1: 444–452, 1976

    Article  PubMed  CAS  Google Scholar 

  • Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clinical Pharmacology and Therapeutics 31: 301–304, 1982

    Article  PubMed  CAS  Google Scholar 

  • Bauer LA, Blouin RA. Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. Clinical Pharmacokinetics 8: 545–549, 1983

    Article  PubMed  CAS  Google Scholar 

  • Beal SL. Computation of the explicit solution to the Michaelis-Menten equation. Journal of Pharmacokinetics and Biopharmaceutics 11: 641–657, 1983

    Article  PubMed  CAS  Google Scholar 

  • Beardsley RS, Freeman JM, Appel FA. Anticonvulsant scrum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia 24: 330–335, 1983

    Article  PubMed  CAS  Google Scholar 

  • Beck DE, Farringer JA, Ravis WR, Robinson CA. Accuracy of three methods for predicting concentrations of free phenytoin. Clinical Pharmacy 6: 888–894, 1987

    PubMed  CAS  Google Scholar 

  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307–310, 1986

    Article  PubMed  CAS  Google Scholar 

  • Blaser KU, Vo>zeh S, Landolt H, Kaufmann G, Romppainen J, et al. Intravenous phenytoin: a loading scheme for desired concentrations. Annals of Internal Medicine 110: 1029–1031, 1989

    PubMed  CAS  Google Scholar 

  • Booker HE, Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 14: 177–184, 1973

    Article  PubMed  CAS  Google Scholar 

  • Borofsky LG, Louis S, Kutt H, Roginsky M. Diphenylhydantoin: efficacy, toxicity, and dose-serum level relationships in children. Journal of Pediatrics 81: 995–1002, 1972

    Article  PubMed  CAS  Google Scholar 

  • Boston Collaborative Drug Surveillance Program. Diphenylhydantoin side effects and serum albumin levels. Clinical Pharmacology and Therapeutics 14: 529–532, 1973

    Google Scholar 

  • Bouma PAD, Peters ACB, Arts RJHM, Stijnen T, Van Rossum J. Discontinuation of antiepileptic therapy: a prospective study in children. Journal of Neurology, Neurosurgery, and Psychiatry 50: 1579–1583, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bryson SM, Al-Lanqawi Y, Kelman AW, Whiting B. Comparison of a Bayesian forecasting technique with a new method for estimating phenytoin dose requirements. Therapeutic Drug Monitoring 10: 80–84, 1988

    PubMed  CAS  Google Scholar 

  • Buchthal F, Svensmark OP, Schiller PJ. Clinical and electroen-cephalographic correlations with serum levels of diphenylhydantoin. Archives of Neurology (Chicago) 2: 624–630, 1960

    Article  CAS  Google Scholar 

  • Burton ME, Vasko MR, Brater DC. Comparison of drug dosing methods. Clinical Pharmacokinetics 10: 1–37, 1985

    Article  PubMed  CAS  Google Scholar 

  • Bussey HI, Hoffman EW. A prospective evaluation of therapeutic drug monitoring. Therapeutic Drug Monitoring 5: 245–248, 1983

    Article  PubMed  CAS  Google Scholar 

  • Cacek AT. Review of alterations in oral phenytoin bioavailability associated with formulation, antacids and food. Therapeutic Drug Monitoring 8: 166–171, 1986

    Article  PubMed  CAS  Google Scholar 

  • Callaghan N, Garrett A, Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years: a prospective study. New England Journal of Medicine 318: 942–946, 1988

    Article  PubMed  CAS  Google Scholar 

  • Callaghan N, Kenny RA, O’Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 48: 639–644, 1985

    Article  PubMed  CAS  Google Scholar 

  • Chiba K, Ishizaki T, Miura H, Minagawa K. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. Journal of Pediatrics 96: 479–484, 1980

    Article  PubMed  CAS  Google Scholar 

  • Choonara IA, Rane A. Therapeutic drug monitoring of anticonvulsants: state of the art. Clinical Pharmacokinetics 18: 318–328, 1990

    Article  PubMed  CAS  Google Scholar 

  • Cobos JE. High-dose phenytoin in the treatment of refractory epilepsy. Epilepsia 28: 111–114, 1987

    Article  PubMed  CAS  Google Scholar 

  • Coleman RW, Krewsun I, Kelber RL. Single feedback Bayesian forecasts with free and total phenytoin concentrations. Clinical Pharmacokinetics 9 (Suppl. 1): 90–92, 1984

    Article  Google Scholar 

  • Crowley JJ, Koup JR, Cusack BJ, Ludden TM, Vestal RE. Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. European Journal of Clinical Pharmacology 32: 141–148, 1987

    Article  PubMed  CAS  Google Scholar 

  • Danhof M, Breimer DD. Therapeutic drug monitoring in saliva. Clinical Pharmacokinetics 3: 39–57,. 1978

    Article  PubMed  CAS  Google Scholar 

  • DeMonaco HJ, Lawless LM. Variability of phenytoin protein binding in epileptic patients. Archives of Neurology 40: 481–483, 1983

    Article  PubMed  CAS  Google Scholar 

  • Dodson WE. Nonlinear kinetics of phenytoin in children. Neurology 32: 42–48, 1982

    Article  PubMed  CAS  Google Scholar 

  • Feeley M, Duggan B, O’Callaghan M, Callaghan N. The therapeutic range for phenytoin — a reappraisal. Irish Journal of Medical Science 2: 44–49, 1979

    Article  Google Scholar 

  • Feldman RG, Pippenger CE. The relation of anticonvulsant drug levels to complete seizure control. Journal of Clinical Pharmacology 16: 51–59, 1976

    PubMed  CAS  Google Scholar 

  • Flint N, Lopez LM, Robinson JD, Williams C, Salem RB. Comparison of eight phenytoin dosing methods in institutionalized patients. Therapeutic Drug Monitoring 7: 74–80, 1985

    Article  PubMed  CAS  Google Scholar 

  • Froscher W, Eichelbaum M, Gugler R, Hildenbrand G, Penin H. A prospective randomized trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. Journal of Neurology 224: 193–201, 1981

    Article  PubMed  CAS  Google Scholar 

  • Gerber N, Wagner JG. Explanation of dose dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Research Communications in Chemical Pathology and Pharmacology 3: 455–466, 1972

    PubMed  CAS  Google Scholar 

  • Godley PJ, Ludden TM, Clementi WA, Godley SE, Ramsey RR. Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrations. Clinical Pharmacy 6: 634–639, 1987

    PubMed  CAS  Google Scholar 

  • Grasela TH, Sheiner LB, Rambeck B, Boenigk HE, Dunlop A, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clinical Pharmacokinetics 8: 355–364, 1983

    Article  PubMed  CAS  Google Scholar 

  • Graves NM, Leppik IE, Termond E, Taylor JW. Phenytoin clearances in a compliant population: description and application. Therapeutic Drug Monitoring 8: 427–433, 1986

    Article  PubMed  CAS  Google Scholar 

  • Haerer AF, Grace JB. Studies of anticonvulsant levels in epileptics. Acta Neurologica Scandinavica 45: 18–31, 1969

    Article  PubMed  CAS  Google Scholar 

  • Ioannides-Demos LL, Horne MK, Tong N, Wodak J, Harrison PM, et al. Impact of a pharmacokinetics consultation service on clinical outcomes in an ambulatory-care epilepsy clinic. American Journal of Hospital Pharmacy 45: 1549–1551, 1988

    PubMed  CAS  Google Scholar 

  • Johnson GJ, Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RFW. Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate — the predictive value of plasma albumin concentration. British Journal of Clinical Pharmacology 27: 843–849, 1989

    Article  PubMed  CAS  Google Scholar 

  • Jung D, Powell JR, Walson P, Perrier D. Effect of dose on phenytoin absorption. Clinical Pharmacology and Therapeutics 28: 479–485, 1980

    Article  PubMed  CAS  Google Scholar 

  • Killilea T, Coleman R, Ludden T, Peck CC, Rose D. Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance. Therapeutic Drug Monitoring 11: 455–462, 1989

    PubMed  CAS  Google Scholar 

  • Kilpatrick CJ, Wanwimolruk S, Wing LMH. Plasma concentrations of unbound phenytoin in the management of epilepsy. British Journal of Clinical Pharmacology 17: 539–546, 1984

    Article  PubMed  CAS  Google Scholar 

  • Knott C, Hamshaw-Thomas A, Reynolds F. Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy. British Medical Journal 284: 13–16, 1982

    Article  PubMed  CAS  Google Scholar 

  • Koch-Weser J. The serum level approach to individualization of drug dosage. European Journal of Clinical Pharmacology 9: 1–8, 1975

    Article  PubMed  CAS  Google Scholar 

  • Koike Y, Magnusson A, Steiner E, Rane A, Sjöqvist F. Ultrafiltration compared with equilibrium dialysis in the determination of unbound phenytoin in plasma. Therapeutic Drug Monitoring 7: 461–465, 1985

    Article  PubMed  CAS  Google Scholar 

  • Koup JR, Gibaldi M, Godolphin W. Single point estimation of phenytoin dosing: a reappraisal. Research Communications in Chemical Pathology and Pharmacology 34: 231–239, 1981

    PubMed  CAS  Google Scholar 

  • Kutt H. Phenytoin: relation of plasma concentration to seizure control. In Woodbury et al. (Eds) Antiepileptic drugs, pp. 241–246, Raven Press, New York, 1982

    Google Scholar 

  • Kutt H, Penry K. Usefulness of blood levels of antiepileptic drugs. Archives of Neurology 31: 283–288, 1974

    Article  PubMed  CAS  Google Scholar 

  • Kutt H, Winters W, Kokenge R, McDowell F. Diphenylhydantoin metabolism, blood levels and toxicity. Archives of Neurology 11: 642–648, 1964

    Article  PubMed  CAS  Google Scholar 

  • Lambie DG, Nanda RN, Johnson RH, Shakir RA. Therapeutic and pharmacokinetic effects of increasing phenytoin in chronic epileptics on multiple drug therapy. Lancet 2: 386–389, 1976

    Article  PubMed  CAS  Google Scholar 

  • Levine M, McCollom R, Chang T, Orr J. Evaluation of serum phenytoin monitoring in an acute care setting. Therapeutic Drug Monitoring 10: 50–57, 1988

    PubMed  CAS  Google Scholar 

  • Levine M, Orr J, Chang T. Evaluation of a nomogram for estimating the rate of phenytoin accumulation. Therapeutic Drug Monitoring 9: 166–170, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Levine M, Orr J, Chang T. Interindividual variation in the extent and rate of phenytoin accumulation. Therapeutic Drug Monitoring 9: 171–176, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Levy RH. Monitoring free drug levels: determination of free concentration versus free fraction. Therapeutic Drug Monitoring 5: 243–244, 1983

    Article  PubMed  CAS  Google Scholar 

  • Ludden TM, Allen JP, Schneider LW, Stavchansky SA. Rate of phenytoin accumulation in man: a simulation study. Journal of Pharmacokinetics and Biopharmaceutics 6: 399–415, 1978

    Article  PubMed  CAS  Google Scholar 

  • Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JM, et al. Individualization of phenytoin dosage regimens. Clinical Pharmacology and Therapeutics 21: 287–293, 1977

    PubMed  CAS  Google Scholar 

  • Ludden TM, Beal SL, Peck CC, Godley PJ. Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentration. Clinical Pharmacy 5: 580–585, 1986

    PubMed  CAS  Google Scholar 

  • Lund L. Effects of phenytoin in patients with epilepsy in relation to its concentration in plasma. In Davies & Prichard (Eds) Biological effects of drugs in relation to their plasma concentrations, pp. 227–238, University Park Press, London, 1973

    Google Scholar 

  • Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels: a prospective three year study in ambulant patients with generalized epileptic seizures. Archives of Neurology 31: 289–294, 1974

    Article  PubMed  CAS  Google Scholar 

  • Lund L, Berlin A, Lunde PKM. Plasma protein binding of diphenylhydantoin in patients with epilepsy: agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid. Clinical Pharmacology and Therapeutics 13: 196–200, 1972

    PubMed  CAS  Google Scholar 

  • Lunde PKM, Rane A, Yaffe SJ, Lund L, Sjoqvist F. Plasma protein binding of diphenylhydantoin in man: interaction with other drugs and the effect of temperature and plasma dilution. Clinical Pharmacology and Therapeutics 11: 846–855, 1970

    PubMed  CAS  Google Scholar 

  • Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 5: 579–596, 1977

    Article  PubMed  CAS  Google Scholar 

  • Mauro LS, Mauro VF, Bachmann KA, Higgins JT. Accuracy of two equations in determining normalized phenytoin concentrations. Drug Intelligence and Clinical Pharmacy 23: 64–68, 1989

    CAS  Google Scholar 

  • McCauley DL, Tozer TN, Winter ME. Time for phenytoin concentration to peak: consequences of first-order and zero-order absorption. Therapeutic Drug Monitoring 11: 540–542, 1989

    Article  PubMed  CAS  Google Scholar 

  • Morrow JI, Richens A. Disposition of anticonvulsants in childhood. Clinical Pharmacokinetics 17 (Suppl. 1): 89–104, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mucklow JC. The use of saliva in therapeutic drug monitoring. Therapeutic Drug Monitoring 4: 229–247, 1982

    Article  CAS  Google Scholar 

  • Mullen PW. Optimal phenytoin therapy: a new technique for individualizing dosage. Clinical Pharmacology and Therapeutics 23: 228–232, 1978

    PubMed  CAS  Google Scholar 

  • Mullen PW, Foster RW. Comparative evaluation of six techniques for determining the Michaelis-Menten parameters relating phenytoin dose and steady-state serum concentrations. Journal of Pharmacy and Pharmacology 3: 100–104, 1979

    Article  Google Scholar 

  • Murphy JE, Bruni J, Stewart RB. Clinical utility of six methods of predicting phenytoin doses and plasma concentrations. American Journal of Hospital Pharmacy 38: 248–354, 1981

    Google Scholar 

  • Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (part 1). Clinical Pharmacokinetics 18: 37–60, 1990

    Article  PubMed  CAS  Google Scholar 

  • Neuvonen PJ. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics 4: 91–103, 1979

    Article  PubMed  CAS  Google Scholar 

  • Paxton JW, Whiting B, Stephen KW. Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. British Journal of Clinical Pharmacology 4: 185–191, 1977

    Article  PubMed  CAS  Google Scholar 

  • Perucca E. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Therapeutic Drug Monitoring 2: 331–334, 1980

    PubMed  CAS  Google Scholar 

  • Perucca E. Free level monitoring of antiepileptic drugs: clinical usefulness and case studies. Clinical Pharmacokinetics 9 (Suppl. 1): 71–78. 1984

    Article  PubMed  Google Scholar 

  • Perucca E, Richens A. Antiepileptic drugs: clinical aspects. In Richens & Marks (Eds) Therapeutic drug monitoring, pp. 320–348, Churchill Livingstone, Edinburgh, 1981a

    Google Scholar 

  • Perucca E, Richens A. Drug interactions with phenytoin. Drugs 21: 120–137, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Peterson GM, McLean S, Aldous S, Von Witt RJ, Millingen K.S. Plasma protein binding of phenytoin in 100 epileptic patients. British Journal of Clinical Pharmacology 14: 298–300, 1982

    Article  PubMed  CAS  Google Scholar 

  • Privitera MD, Homan RW, Ludden TM, Peck CC, Vasko MR. Clinical utility of a Bayesian dosing program for phenytoin. Therapeutic Drug Monitoring 11: 285–294, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rambeck B, Boenigk HE, Dunlop A, Mullen PW, Wadsworth J, et al. Predicting phenytoin dose — a revised nomogram. Therapeutic Drug Monitoring 1: 325–333, 1979

    Article  PubMed  CAS  Google Scholar 

  • Rawson MD. Diphenylhydantoin intoxication and cerebrospinal fluid protein. Neurology 18: 1009–1011, 1968

    Article  PubMed  CAS  Google Scholar 

  • Record KE, Rapp RP, Young AB, Kostenbauder HB. Oral phenytoin loading in adults: rapid achievement of therapeutic plasma levels. Annals of Neurology 5: 268–270, 1979

    Article  PubMed  CAS  Google Scholar 

  • Reynolds EH. Early treatment and prognosis of epilepsy. Epilepsia 28: 97–106, 1987

    Article  PubMed  CAS  Google Scholar 

  • Reynolds EH, Chadwick D, Galbraith AW. One drug (phenytoin) in the treatment of epilepsy. Lancet 1: 923–926, 1976

    Article  PubMed  CAS  Google Scholar 

  • Reynolds EH, Shorvon SD, Galbraith AW, Chadwick D, Dellaportas CI, et al. Phenytoin monotherapy for epilepsy: a long-term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia 22: 475–488, 1981

    Article  PubMed  CAS  Google Scholar 

  • Reynolds EH, Trimble MR. Adverse neuropsychiatric effects of anticonvulsant drugs. Drugs 29: 570–581, 1985

    Article  PubMed  CAS  Google Scholar 

  • Richens A. Clinical pharmacokinetics of phenytoin. Clinical Pharmacokinetics 4: 153–169, 1979

    Article  PubMed  CAS  Google Scholar 

  • Rimmer EM, Buss DC, Routledge PA, Richens A. Should we routinely measure free plasma phenytoin concentration? British Journal of Clinical Pharmacology 17: 99–102, 1984

    Article  PubMed  CAS  Google Scholar 

  • Ritschel WA, Alcorn GJ, Johnson RD, Rao S, Fogelson MH. Evaluation of a phenytoin dosage regimen design and adjustment computer program. Therapeutic Drug Monitoring 11: 437–449, 1989

    PubMed  CAS  Google Scholar 

  • Rowland M. Protein binding and drug clearance. Clinical Pharmacokinetics 9 (Suppl. 1): 10–17, 1984

    Article  PubMed  CAS  Google Scholar 

  • Sawchuk RJ, Pepin SM, Leppik IE, Gumnit RJ. Rapid and slow release phenytoin in epileptic patients at steady-state: assessment of relative bioavailability utilizing Michaelis-Menten parameters. Journal of Pharmacokinetics and Biopharmaceutics 10: 383–391, 1982

    Article  PubMed  CAS  Google Scholar 

  • Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobar-bital and carbamazepine. Archives of Neurology 43: 263–265, 1986

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 8: 553–571, 1980

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 9: 503–512, 1981

    Article  PubMed  CAS  Google Scholar 

  • Sheiner LB, Beal SL, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clinical Pharmacology and Therapeutics 26: 294–305, 1979

    PubMed  CAS  Google Scholar 

  • Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In Melmon & Morrelli (Eds) Clinical pharmacology, 2nd ed., pp. 71–109, McMillan Publishing, New York, 1978

    Google Scholar 

  • Shorvon SD, Reynolds EH. Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. Journal of Neurology. Neurosurgery and Psychiatry 45: 620–626, 1982

    Article  CAS  Google Scholar 

  • Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Clinical Pharmacology and Therapeutics 43: 345–353, 1988

    Article  PubMed  CAS  Google Scholar 

  • Svensson CK, Woodruff MN, Lalka D. Influence of protein binding and use of unbound (free) drug concentrations. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., Applied Therapeutics Inc., Spokane, 1986

    Google Scholar 

  • Taylor JW, Murphy MJ, Berg MJ, Perry PJ, Lyon LW, et al. Phenytoin dosage requirements and pharmacokinetic variables. Clinical Pharmacy 2: 253–257, 1983

    PubMed  CAS  Google Scholar 

  • Toscano JP, Jameson JP. Comparison of four single-point phenytoin dosage prediction techniques using computer-simulated pharmacokinetic values. Clinical Pharmacy 5: 396–402, 1986

    PubMed  CAS  Google Scholar 

  • Troupin AS. The measurement of anticonvulsant agent levels. Annals of Internal Medicine 100: 854–858, 1984

    PubMed  CAS  Google Scholar 

  • Troupin AS, Friel P. Anticonvulsant level in saliva, serum and cerebrospinal fluid. Epilepsia 16: 223–227, 1975

    Article  PubMed  CAS  Google Scholar 

  • Troupin AS, Ojemann LM. Paradoxical intoxication — a complication of anticonvulsant administration. Epilepsia 16: 753–758, 1975

    Article  PubMed  CAS  Google Scholar 

  • Vajda FJE, Aicardi J. Reassessment of the concept of a therapeutic range of anticonvulsant plasma levels. Developmental Medicine and Child Neurology 25: 660–671, 1983

    Article  PubMed  CAS  Google Scholar 

  • Vo>zeh S, Follath F. Nomographic estimation of time to reach steady-state serum concentration during phenytoin therapy. European Journal of Clinical Pharmacology 17: 33–35, 1980

    Article  Google Scholar 

  • Vo>zeh S, Koelz A, Martin E, Magun H, Scollo-Lavizzari G, et al. Predictability of phenytoin serum levels by nomograms and clinicians. European Neurology 19: 345–352, 1980

    Article  Google Scholar 

  • Vo>zeh S, Muir K, Sheiner LB, Follath F. Predicting individual phenytoin dosage. Journal of Pharmacokinetics and Biopharmaceutics 9: 131–146, 1981

    Article  Google Scholar 

  • Vo>zeh S, Uematsu T, Aarons L, Maitre P, Landolt H, et al. Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus: a population pharmacokinetic study. Clinical Pharmacokinetics 14: 122–128, 1988

    Article  Google Scholar 

  • Wagner JG. Time to reach steady-state and prediction of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics. Journal of Pharmacokinetics and Biopharmaceutics 6: 209–225, 1978

    Article  PubMed  CAS  Google Scholar 

  • Wagner JG. New and simple method to predict dosage of drugs obeing simple Michaelis-Menten elimination kinetics and to distinguish such kinetics from simple first order and from parallel Michaelis-Menten and first order kinetics. Therapeutic Drug Monitoring 7: 377–386, 1985

    Article  PubMed  CAS  Google Scholar 

  • Wenk M, Vo>zeh S, Follath F. Serum level monitoring of antibacterial drugs: a review. Clinical Pharmacokinetics 9: 475–492, 1984

    Article  PubMed  CAS  Google Scholar 

  • Wing DS, Duff HJ. The impact of a therapeutic drug monitoring program for phenytoin. Therapeutic Drug Monitoring 11: 32–37, 1989

    Article  PubMed  CAS  Google Scholar 

  • Winter M, Tozer TN. Phenytoin. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 493–539, Applied Therapeutics Inc., Spokane, 1986

    Google Scholar 

  • Woo E, Chan YM, Yu YL, Chan W, Huang CY. If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 29: 129–139, 1988

    Article  PubMed  CAS  Google Scholar 

  • Yuen GJ, Latimer PT, Littlefield LC, Mackey RW. Phenytoin dosage predictions in pediatric patients. Clinical Pharmacokinetics 16: 254–260, 1989

    Article  PubMed  CAS  Google Scholar 

  • Yuen GJ, Taylor JW, Ludden TM, Murphy MJ. Predicting phenytoin dosages using Bayesian feedback: a comparison with other methods. Therapeutic Drug Monitoring 5: 437–441, 1983

    Article  PubMed  CAS  Google Scholar 

  • Yukawa E, Higuchi S, Aoyama T. Evaluation of single-point phenytoin dosage prediction methods in pediatric patients. Journal of Pharmacobio-Dynamics 11: 736–743, 1988

    Article  PubMed  CAS  Google Scholar 

  • Zaccara G, Messori A, Muscas GC, Albani F, Baruzzi A, et al. Predictive performance of pharmacokinetic methods for phenytoin dosing: a multi-center evaluation in 282 patients with epilepsy. Epilepsy Research 3: 253–261, 1989

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall, Vancouver, British Columbia, V6T 1W5, Canada

    Marc Levine & Tom Chang

  2. Departments of Medicine and Pharmacy, University Hospital, Vancouver, British Columbia, Canada

    Marc Levine & Tom Chang

Authors
  1. Marc Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tom Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levine, M., Chang, T. Therapeutic Drug Monitoring of Phenytoin Rationale and Current Status. Clin Pharmacokinet 19, 341–358 (1990). https://doi.org/10.2165/00003088-199019050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199019050-00001

Keywords

Search

Navigation